Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.93)
# 168
Out of 4,468 analysts
217
Total ratings
69.9%
Success rate
40.6%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintained: Buy | $33 | $23.07 | +43.04% | 6 | Jun 4, 2026 | |
| AVLN Avalyn Pharma | Initiated Coverage: Buy | $51 | $29.73 | +71.54% | 1 | May 26, 2026 | |
| ABBV AbbVie | Rated: Buy | $236 → $235 | $261.07 | -9.99% | 17 | May 15, 2026 | |
| SRPT Sarepta Therapeutics | Maintained: Hold | $20 → $19 | $19.28 | -1.45% | 27 | May 15, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $24 → $26 | $19.40 | +34.02% | 11 | May 15, 2026 | |
| ASND Ascendis Pharma | Rated: Buy | $324 → $329 | $274.50 | +19.85% | 13 | May 15, 2026 | |
| ARGX argenx SE | Rated: Buy | $1,007 → $1,059 | $939.68 | +12.70% | 12 | May 15, 2026 | |
| CRNX Crinetics Pharmaceuticals | Rated: Buy | $90 → $88 | $42.23 | +108.38% | 5 | May 15, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $95 → $91 | $41.20 | +120.87% | 7 | May 15, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $34 → $33 | $33.47 | -1.40% | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $88 → $120 | $94.34 | +27.20% | 9 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $126 → $138 | $125.59 | +9.88% | 19 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 | $56.92 | -8.64% | 7 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $295 → $300 | $375.07 | -20.01% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 | $20.92 | +210.71% | 3 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $18 | $13.92 | +29.31% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $0.4283 | +1,534.37% | 7 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $29.98 | +53.44% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 → $26 | $44.19 | -41.16% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $208 | $111.60 | +86.38% | 6 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $9.84 | +72.76% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $55 | $12.96 | +324.38% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 | $13.62 | -41.26% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 | $15.82 | -49.42% | 6 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.81 | +176.24% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $3.84 | +30.21% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $2.20 | +81.82% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4 | $3.19 | +25.39% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $5.30 | n/a | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $4.30 | n/a | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $78 | $116.86 | n/a | 1 | Aug 3, 2022 |
Dyne Therapeutics
Jun 4, 2026
Maintained: Buy
Price Target: $33
Current: $23.07
Upside: +43.04%
Avalyn Pharma
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $29.73
Upside: +71.54%
AbbVie
May 15, 2026
Rated: Buy
Price Target: $236 → $235
Current: $261.07
Upside: -9.99%
Sarepta Therapeutics
May 15, 2026
Maintained: Hold
Price Target: $20 → $19
Current: $19.28
Upside: -1.45%
Viridian Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $19.40
Upside: +34.02%
Ascendis Pharma
May 15, 2026
Rated: Buy
Price Target: $324 → $329
Current: $274.50
Upside: +19.85%
argenx SE
May 15, 2026
Rated: Buy
Price Target: $1,007 → $1,059
Current: $939.68
Upside: +12.70%
Crinetics Pharmaceuticals
May 15, 2026
Rated: Buy
Price Target: $90 → $88
Current: $42.23
Upside: +108.38%
Vera Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $95 → $91
Current: $41.20
Upside: +120.87%
Ultragenyx Pharmaceutical
May 11, 2026
Maintained: Buy
Price Target: $34 → $33
Current: $33.47
Upside: -1.40%
May 11, 2026
Maintained: Buy
Price Target: $88 → $120
Current: $94.34
Upside: +27.20%
May 7, 2026
Maintained: Buy
Price Target: $126 → $138
Current: $125.59
Upside: +9.88%
May 5, 2026
Maintained: Buy
Price Target: $52
Current: $56.92
Upside: -8.64%
May 5, 2026
Maintained: Buy
Price Target: $295 → $300
Current: $375.07
Upside: -20.01%
May 4, 2026
Maintained: Buy
Price Target: $65
Current: $20.92
Upside: +210.71%
Apr 1, 2026
Maintained: Buy
Price Target: $20 → $18
Current: $13.92
Upside: +29.31%
Apr 1, 2026
Maintained: Buy
Price Target: $12 → $7
Current: $0.4283
Upside: +1,534.37%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $29.98
Upside: +53.44%
Mar 2, 2026
Maintained: Buy
Price Target: $24 → $26
Current: $44.19
Upside: -41.16%
Feb 26, 2026
Maintained: Buy
Price Target: $208
Current: $111.60
Upside: +86.38%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $9.84
Upside: +72.76%
Feb 10, 2026
Maintained: Buy
Price Target: $40 → $55
Current: $12.96
Upside: +324.38%
Feb 6, 2026
Maintained: Hold
Price Target: $8
Current: $13.62
Upside: -41.26%
Dec 18, 2025
Maintained: Hold
Price Target: $8
Current: $15.82
Upside: -49.42%
Dec 17, 2025
Maintained: Buy
Price Target: $5
Current: $1.81
Upside: +176.24%
Dec 17, 2025
Maintained: Hold
Price Target: $5
Current: $3.84
Upside: +30.21%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $2.20
Upside: +81.82%
Dec 17, 2025
Maintained: Hold
Price Target: $4
Current: $3.19
Upside: +25.39%
Dec 20, 2024
Reiterated: Buy
Price Target: $20 → $18
Current: $5.30
Upside: n/a
May 30, 2023
Maintained: Buy
Price Target: $10
Current: $4.30
Upside: n/a
Aug 3, 2022
Downgraded: Hold
Price Target: $78
Current: $116.86
Upside: n/a